Ozanimod as induction and maintenance therapy for ulcerative colitis.

Volume: 385, Issue: 14, Pages: 1280 - 1291
Published: Sep 30, 2021
Abstract
Background null Ozanimod, a selective sphingosine-1-phosphate receptor modulator, is under investigation for the treatment of inflammatory bowel disease. null Methods null We conducted a phase 3, multicenter, randomized, double-blind, placebo-controlled trial of ozanimod as induction and maintenance therapy in patients with moderately to severely active ulcerative colitis. In the 10-week induction period, patients in cohort 1 were assigned to...
Paper Details
Title
Ozanimod as induction and maintenance therapy for ulcerative colitis.
Published Date
Sep 30, 2021
Volume
385
Issue
14
Pages
1280 - 1291
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.